TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS.
D010131:Aminosalicylic Acid; D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D001431:Bacteriological Techniques; D035843:Biomedical Research; D003523:Cycloserine; D004351:Drug Resistance; D004352:Drug Resistance, Microbial; D005000:Ethionamide; D007538:Isoniazid; D011044:Poland; D011718:Pyrazinamide; D013183:Sputum; D013307:Streptomycin; D014116:Toxicology; D014376:Tuberculosis; D014397:Tuberculosis, Pulmonary
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D010131:Aminosalicylic Acid; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D013307:Streptomycin
AMINOSALICYLIC ACID; BACTERIOLOGICAL TECHNICS; CLINICAL RESEARCH; CYCLOSERINE; DRUG RESISTANCE, MICROBIAL; ETHIONIAMIDE; ISONIAZID; POLAND; PYRAZINAMIDE; SPUTUM; STREPTOMYCIN; TOXICOLOGIC REPORT; TUBERCULOSIS, PULMONARY